SCHEMBL2177059

SCHEMBL2177059

CC(C)C(C(=O)O)N1Cc2cc(-c3ccc(NC(=S)Nc4cccc(Cl)c4)cc3)ccc2C1=O

nearest known ligand 0.52

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
SDCBP O00560 4/20 0.52
SDC2 P34741 4/20 0.52
DGAT1 O75907 2/20 0.47
LMNA P02545 1/20 0.42
TP53 P04637 1/20 0.42
MEN1 O00255 1/20 0.41
ALDH1A1 P00352 1/20 0.41
MAOA P21397 1/20 0.41
MAOB P27338 1/20 0.41
KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2177051 1.00 SDCBP (0.52) SDCBPSDC2DGAT1LMNATP53
SCHEMBL2179028 0.93 SDCBP (0.45) SDCBPSDC2DGAT1LMNATP53
SCHEMBL2176682 0.92 SDCBP (0.56) SDCBPSDC2DGAT1LMNATP53
SCHEMBL2176688 0.92 SDCBP (0.56) SDCBPSDC2DGAT1LMNATP53
SCHEMBL2179511 0.89 DGAT1 (0.47) SDCBPSDC2DGAT1LMNATP53
SCHEMBL2180663 0.89 DGAT1 (0.47) SDCBPSDC2DGAT1LMNATP53
SCHEMBL2177510 0.88 LMNA (0.52) SDCBPSDC2DGAT1LMNATP53
SCHEMBL2177019 0.88 LMNA (0.52) SDCBPSDC2DGAT1LMNATP53
SCHEMBL2181755 0.87 DGAT1 (0.49) SDCBPSDC2DGAT1LMNATP53
SCHEMBL2178008 0.87 DGAT1 (0.49) SDCBPSDC2DGAT1LMNATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US claimed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US claimed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP claimed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO claimed
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US disclosed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US disclosed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP disclosed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE DGAT1, DGAT2, LCAT SDCBP 2373/4885SDC2 3855/4885DGAT1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.